Mild haemophilia: a disease with many faces and many unexpected pitfalls.
Despite major advances in diagnosis and treatment, the management of patients with mild haemophilia (MH) remains a major challenge. Mild haemophilia is defined by factor levels between 0.05 and 0.40 IU mL(-1). The bleeding associated with mild haemophilia is most frequently episodic, occurring during surgery or following trauma. Spontaneous bleeding is rare. Diagnosis is sometimes delayed because of insensitivity of screening clotting assays or discrepancies in factor VIII activity as measured by different assays. The treatment of choice in mild haemophilia A is desmopressin, which typically induces a 2-6-fold increase of factor VIII over baseline. However, desmopressin has its limitations in this setting such as the occurrence of tachyphylaxis and failure to respond in an undetermined proportion of patients. Factors underlying poor biological response or magnitude of response to desmopressin are incompletely understood. Inhibitor development in mild haemophilia is particularly distressing. This complication arises at an older age in this patient group because of infrequent need for factor VIII replacement. Inhibitors in mild haemophilia patients often cross-react with endogenous factor VIII resulting in severe spontaneous bleeding frequently in a postoperative setting. Intensive perioperative use of factor VIII and some specific mutations induce a particularly high risk for inhibitor development, but risk factors are incompletely understood. For reasons of the older age of the patients, treatment of bleeding with bypassing agents may cause major thrombotic complications. Data on therapeutic options for inhibitor eradication in patients with mild haemophilia are particularly scarce. With increased life-expectancy for all haemophilia patients, the group of elderly patients with mild haemophilia requiring major surgery will further increase. Prevention of inhibitors, particularly in this patient group, should be a major topic of interest in both clinic and research.
Peerlinck
K
K
Hemophilia Center, Universitaire Ziekenhuizen Leuven and Center for Molecular and Vascular Biology, Katholieke Universiteit Leuven, Leuven, Belgium. kathelijne.peerlinck@uzleuven.be
Jacquemin
M
M
D019774:Blood Coagulation Factor Inhibitors / Q000097:blood; D001779:Blood Coagulation Factors / Q000032:analysis*; D001780:Blood Coagulation Tests / Q000379:methods*; D003894:Deamino Arginine Vasopressin / Q000627:therapeutic use*; D006467:Hemophilia A / Q000097:blood / Q000175:diagnosis* / Q000628:therapy*; D006490:Hemostatics / Q000627:therapeutic use*; D006801:Humans
D019774:Blood Coagulation Factor Inhibitors; D001779:Blood Coagulation Factors; D006490:Hemostatics; D003894:Deamino Arginine Vasopressin